IASIC Speaker Series Presents Cannabis and Psychosis

The International Academy on the Science and Impact of Cannabis (IASIC) is excited to present the IASIC Speaker Series. Presented free of charge, this ongoing educational seminar series will focus on the science, data and peer-reviewed research surrounding marijuana and will be led by international medical experts. This non-partisan and non-political series is continually developed, organized, and guided by doctors.

 

Presented By: Brian Miller, MD, PhD, MPH
Date: Tuesday, November 23, 2021
Time: 1:00PM Eastern/10:00AM Pacific
Price: FREE

Substance use comorbidity in psychotic disorders has been described as “the rule rather than the exception”, and is often deleterious to the clinical course of illness. Cannabis (marijuana) is one of the most commonly used substances by patients with schizophrenia and related psychotic disorders. Modulation of the endocannabinoid system by the main psychoactive component in marijuana, Δ9-tetrahydrocannabinol, can induce acute psychosis and cognitive impairment. Over the past two decades, there has been extensive research on the association between cannabis and psychosis. The purpose of this presentation is to synthesize recent research in this area, including associations between cannabis and psychosis risk; the epidemiology and phenomenology of psychosis and comorbid cannabis use; and associations between cannabis use and clinical course, and outcomes in psychosis.

Like this article?

Share on Facebook
Share on Twitter
Share on Linkdin
Share on Pinterest

Related Posts

IASIC Speaker Series Presents  Cannabis and Mental Health

The International Academy on the Science and Impact of Cannabis (IASIC) is excited to present the IASIC Speaker Series. Presented free of charge, this ongoing educational seminar series will focus on the science, data and peer-reviewed research surrounding marijuana and will be led by international medical experts. This non-partisan and non-political series is continually developed,

Placebo Effect a Major Driver of Pain Reduction in Cannabis Trials

A strong placebo response may be largely responsible for the significant pain reduction observed in clinical trials of cannabis-based therapies, results of a new meta-analysis suggest. Investigators found that while the effect size of cannabinoids on pain intensity was significant, the placebo effect was about the same. “The data from the present meta-analysis, including 1459

Trends in Cannabis Use Disorder Diagnoses in the U.S. Veterans Health Administration, 2005–2019

Since 2005, diagnoses of cannabis use disorder have increased substantially among VHA patients, as they have in the general population and other patient populations. Possible explanations warranting investigation include decreasing perception of risk, changing laws, increasing cannabis potency, stressors related to growing socioeconomic inequality, and use of cannabis to self-treat pain. Clinicians and the public

Cannabis legalization and cannabis-involved pregnancy hospitalizations in Colorado

The primary objective of this study was to evaluate the association between presence of recreational cannabis dispensaries and prevalence of cannabis-involved pregnancy hospitalizations in Colorado. This was a retrospective cohort study of pregnancy-related hospitalizations co-coded with cannabis diagnosis codes in the Colorado Hospital Association from January 1, 2011, through December 31, 2018 (recreational cannabis began

Scroll to Top